iRhythm Holdings, Inc (IRTC) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello, everyone. Thank you for attending today's iRhythm Holdings, Inc Q4 2025 earnings conference call. My name is William, and I will be your moderator today. (Operator Instructions)

    大家好。感謝您參加今天 iRhythm Holdings, Inc 2025 年第四季財報電話會議。我叫威廉,今天我將擔任主持人。(操作說明)

  • At this time, I would now like to pass the conference over to our host, Stephanie Zhadkevich, Senior Director of Investor Relations with iRhythm. Stephanie?

    此時此刻,我想把會議交給我們的主持人,iRhythm 投資者關係高級總監 Stephanie Zhadkevich。史蒂芬妮?

  • Stephanie Zhadkevich - Senior Director of Investor Relations

    Stephanie Zhadkevich - Senior Director of Investor Relations

  • Thank you all for participating in today's call. Earlier today, iRhythm released financial results for the fourth quarter and full year ended December 31, 2025.

    感謝各位參加今天的電話會議。今天早些時候,iRhythm 發布了截至 2025 年 12 月 31 日的第四季度和全年財務業績。

  • Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical fact should be deemed to be forward-looking statements.

    在開始之前,我想提醒各位,管理層將在本次電話會議中發表聲明,其中包括根據 1995 年《私人證券訴訟改革法案》安全港條款,符合聯邦證券法定義的前瞻性聲明。本次電話會議中任何非歷史事實的陳述均應視為前瞻性陳述。

  • These are based upon our current estimates and various assumptions and reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. These statements involve risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors section of our most recent annual report on Form 10-K filed with the Securities and Exchange Commission.

    這些預測是基於我們目前的估計和各種假設,反映了管理層對未來事件、策略、競爭、產品、營運計劃和績效的意圖、信念和期望。這些聲明涉及風險和不確定性,可能導致實際結果或事件與這些前瞻性聲明中預期或暗示的結果或事件有重大差異。因此,您不應過度依賴這些說法。有關我們業務相關的風險和不確定性的清單和說明,請參閱我們向美國證券交易委員會提交的最新年度報告(10-K 表格)中的風險因素部分。

  • Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures and should be read together with the most directly comparable GAAP financial measures. Please refer to the tables in our earnings release and 10-K for a reconciliation of these measures to their most directly comparable GAAP financial measures. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, February 19, 2026.

    我們今天的討論也將包括一些不符合公認會計原則(GAAP)計算的財務指標。我們認為這些非GAAP財務指標提供了與我們業務表現相關的額外資訊。這些非GAAP財務指標應與最直接可比較的GAAP財務指標一起閱讀。請參考我們的獲利報告和 10-K 表格,以了解這些指標與其最直接可比較的 GAAP 財務指標的調整。本次電話會議包含有時效性的信息,僅截至 2026 年 2 月 19 日直播當天的資訊準確無誤。

  • iRhythm disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

    iRhythm 聲明,除法律要求外,無論由於新資訊、未來事件或其他原因,均無意願或義務更新或修改任何財務預測或前瞻性聲明。

  • And with that, I'll turn the call over to Quentin Blackford, iRhythm's President and CEO.

    接下來,我將把電話交給 iRhythm 的總裁兼執行長昆汀布萊克福德。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Thank you, Stephanie. Good afternoon, everyone, and thank you for joining us. I'm pleased to be here with Dan Wilson, our Chief Financial Officer, to discuss our fourth quarter and full year 2025 performance and how we're positioning the company for 2026 and beyond. Dan will walk through our financials shortly, but I want to begin by framing where we stand today and where we're headed. 2025 was a breakout year for iRhythm.

    謝謝你,斯蒂芬妮。各位下午好,感謝各位的參與。我很高興能與我們的財務長丹·威爾遜一起,討論我們 2025 年第四季度和全年的業績,以及我們如何為 2026 年及以後的發展做好準備。Dan稍後會詳細介紹我們的財務狀況,但我想先概述我們目前的狀況以及未來的發展方向。 2025年是iRhythm的突破之年。

  • We delivered strong volume-led revenue growth and meaningfully expanded margins as we exited the year with momentum across cardiology, primary care, innovative channels and international markets. At the same time, we strengthened the underlying platform that will fuel the next several years of value creation. Growth in the quarter and for the full year continued to be driven by volume across all channels. With growth in the fourth quarter of 27%, this marked our fifth consecutive quarter of revenue growth above 20%, reinforcing the durability of our platform and breadth of our growth drivers.

    在心臟病學、初級保健、創新通路和國際市場等領域,我們實現了強勁的銷售驅動型收入成長,並顯著擴大了利潤率,在年底保持了強勁的成長勢頭。同時,我們加強了底層平台,這將為未來幾年的價值創造提供動力。本季和全年的成長繼續由所有通路的銷售推動。第四季成長 27%,這標誌著我們連續第五個季度營收成長超過 20%,鞏固了我們平台的持久性和成長驅動因素的廣泛性。

  • Our leadership in long-term continuous monitoring remains strong with nearly 72% share in a segment growing in the high teens, supported by more than 135 scientific publications to date. On profitability, we also made great progress as we reached a key inflection point, finishing the year with positive free cash flow results for the first time in our company's history and exceeding expectations with respect to adjusted EBITDA margins.

    我們在長期連續監測領域的領先地位依然穩固,在該領域佔據近 72% 的市場份額,且該領域正以接近 10% 的速度增長,迄今為止,我們已發表了 135 多篇科學出版物來支持這一觀點。在獲利能力方面,我們也取得了巨大進步,達到了一個關鍵的轉折點,公司歷史上首次實現了全年自由現金流為正,並且在調整後的 EBITDA 利潤率方面也超出了預期。

  • In the fourth quarter, adjusted EBITDA margins meaningfully exceeded the 15% goal that we have identified as we approach $1 billion in revenue, demonstrating the profitable scalability of our business, but this year was about more than financial milestones -- is about validating the strategic direction we've set, moving from episodic detection to proactive, integrated and increasingly predictive care.

    在第四季度,調整後的 EBITDA 利潤率顯著超過了我們為實現 10 億美元的營收目標而設定的 15% 的目標,這表明我們業務具有盈利的可擴展性。但今年的意義遠不止於財務里程碑,更在於驗證我們所製定的策略方向,即從偶發性檢測轉向主動、全面且日益預測性的照護。

  • The need for long-term continuous monitoring continues to grow. Arrhythmias remain episodic, often invisible until they cause downstream complications, and they are consistently missed by short duration or symptom-driven diagnostics. Data demonstrates that nearly 65% of all arrhythmias, whether symptomatic or asymptomatic are found after 48 hours of monitoring, reinforcing the need for longer duration, yet nearly 2 million short duration Holter and event monitors continue to be prescribed in the US market on an annual basis. We estimate that at least 27 million people in the US are living with significant risk of undiagnosed arrhythmias, a staggering and costly gap in care.

    長期連續監測的需求持續成長。心律不整總是間歇性的,往往在引起後續併發症之前難以察覺,而且由於持續時間短或以症狀為導向的診斷方法,常常會被漏診。數據顯示,近 65% 的心律不整(無論有症狀或無症狀)在 48 小時監測後被發現,這凸顯了延長監測時間的必要性,然而,美國市場每年仍開出近 200 萬個短時程的動態心電圖和事件監測儀。我們估計,美國至少有 2,700 萬人面臨未確診心律不整的重大風險,這是醫療領域一個令人震驚且代價高昂的缺口。

  • At the same time, the health care system is constrained. Nearly half of US counties and close to 90% of rural counties have no cardiologists. Access is not improving, which means the point of arrhythmia detection must shift. In 2025, we demonstrated the power of enabling that shift.

    同時,醫療衛生系統也面臨許多限制。美國近一半的縣和近 90% 的農村縣沒有心臟科醫生。醫療服務取得途徑沒有改善,這意味著心律不整的檢測點必須轉移。2025年,我們展現了推動這種轉變的力量。

  • More than one-third of our volume originated in primary care settings, supported by our expanding footprint in integrated delivery networks, HR integrated workflows and innovative channel partnerships. We now serve approximately 40,000 primary care physicians, creating a scalable proactive care model that aligns with the growing focus on value-based care and population health. This is not a shift away from cardiology. Rather, it expands the market for these important customers as our ability to help Rule-in/Rule-out patients can enable cardiology to focus on the highest acuity patients, while primary care becomes an effective front door for earlier detection meeting the majority of our patients where they are most often being seen.

    超過三分之一的業務量來自初級保健機構,這得益於我們在綜合服務網絡、人力資源整合工作流程和創新通路合作夥伴關係方面不斷擴大的業務範圍。我們現在為大約 40,000 名初級保健醫生提供服務,創建了一種可擴展的主動護理模式,與日益重視基於價值的護理和人群健康的趨勢相一致。這並非偏離心臟病學領域。相反,它擴大了這些重要客戶的市場,因為我們幫助確診/排除患者的能力可以讓心臟科專注於病情最嚴重的患者,而初級保健則成為早期發現的有效入口,在大多數患者最常就診的地方為他們提供服務。

  • Helping to fuel this move upstream is the power of our EHR integration strategy. More than half of our volume now flows through EHR integrated accounts, and 75 of our top 100 customers are fully integrated. These integrations are not simply workflow enhancements, they create meaningful stickiness, increased prescribing consistency and drive long-term account durability.

    推動這一向上游遷移的是我們電子病歷整合策略的力量。現在,我們超過一半的業務量都透過整合 EHR 的帳戶進行,我們前 100 名客戶中有 75 名已完全整合。這些整合不僅僅是工作流程的改進,它們還能創造有意義的顧客黏性,提高處方一致性,並推動帳戶的長期穩定發展。

  • We also advanced our predictive AI capabilities significantly in 2025. With nearly 3 billion hours of curated ECG data, we're now combining internal and external data sets such as claims and EHR information to identify patients at risk of arrhythmias before diagnosis. Early pilots through our partnership with Lucem Health show more than 85% accuracy in pre-identifying patients with clinically relevant arrhythmias.

    2025年,我們也大幅提升了預測性人工智慧能力。我們擁有近 30 億小時的精選心電圖數據,現在正將內部和外部數據集(如索賠和電子健康記錄資訊)結合起來,以便在診斷之前識別有心律不整風險的患者。透過與 Lucem Health 的合作,早期試點計畫顯示,在預先識別具有臨床意義的心律不整患者方面,準確率超過 85%。

  • While early, these programs reaffirm our conviction that iRhythm is positioned not just to detect disease but to help predict risk earlier and ultimately to help prevent it. Our initial programs focus on high-risk populations such as patients with diabetes, CKD, CAD, COPD, sleep and heart failure, where arrhythmias are common and costly. These programs are not just about diagnosing more patients, they are focused on doing so in a way that improves the efficiency, quality and cost of care delivery.

    雖然這些項目還處於早期階段,但它們再次印證了我們的信念:iRhythm 不僅可以檢測疾病,還可以幫助更早預測風險,並最終幫助預防疾病。我們的初步計劃重點關注高風險族群,例如糖尿病、慢性腎臟病、冠狀動脈心臟病、慢性阻塞性肺病、睡眠障礙和心臟衰竭患者,這些人群中心律失常很常見且治療費用昂貴。這些計畫不僅是為了診斷更多的病人,而是致力於以提高醫療服務的效率、品質和降低成本的方式來診斷病人。

  • Zio provides a definitive diagnosis, enabling providers to stratify risk, route patients appropriately and reduce unnecessary downstream health care utilization, resulting in early indications of better patient outcomes and reduce cost of care. As an independent diagnostic provider, iRhythm delivers objective, clinically validated results that integrate directly into existing workflows and care pathways, which helps protect providers and systems and increasingly audit sensitive risk-bearing environments.

    Zio 提供明確的診斷,使醫療服務提供者能夠對風險進行分層,合理安排患者,減少不必要的後續醫療保健利用,從而儘早發現更好的患者預後並降低醫療成本。作為一家獨立的診斷提供者,iRhythm 提供客觀、經臨床驗證的結果,可直接整合到現有的工作流程和護理路徑中,這有助於保護醫療服務提供者和系統,並日益審核敏感的風險環境。

  • Within our MCT business, our current Zio AT offering continues to perform exceptionally well, with unit growth running more than twice the company average for the year. The strength continues to be supported by new account wins, expanding utilization within existing accounts and increased prescribing alongside Zio Monitor. This notable and sustained performance even before bringing an exciting new product to market, reinforces our view that Zio AT is a durable growth driver resonating with physicians today and that we will continue to gain market share in the near term.

    在我們的 MCT 業務中,我們目前的 Zio AT 產品持續表現出色,其銷售成長是該公司全年平均水準的兩倍多。新客戶的贏得、現有客戶使用量的增加以及與 Zio Monitor 合作帶來的處方量成長,都持續支撐著這一強勁勢頭。即使在推出令人興奮的新產品之前,Zio AT 也取得了顯著且持續的業績,這更加堅定了我們的觀點,即 Zio AT 是一個持久的增長驅動力,能夠引起當今醫生的共鳴,並且我們將在短期內繼續獲得市場份額。

  • Consistent with our prior comments, we are incredibly excited about our next-gen MCT device, featuring a 21-day wear time, an improved form factor aligned with our Zio Monitor and enhanced algorithms which is currently under FDA review. We remain in active dialogue with the agency as we work through their questions and continue to expect to release the product in the first half of 2027.

    與我們先前的評論一致,我們對下一代 MCT 設備感到無比興奮,該設備具有 21 天的佩戴時間、與我們的 Zio Monitor 相一致的改進外形以及增強的演算法,目前正在接受 FDA 的審查。我們正在與該機構保持積極對話,努力解決他們提出的問題,並繼續期待在 2027 年上半年發布該產品。

  • We believe the combination of a strong Zio AT offering today and a thoughtfully architected next-generation device sets us up to meaningfully expand our presence in the MCT market, where we hold roughly 15% market share compared to our 72% market share in long-term cardiac monitoring. Every 10 points of market share gains represents roughly $80 million to $100 million of incremental annual revenue.

    我們相信,憑藉目前強大的 Zio AT 產品和精心設計的下一代設備,我們能夠大幅擴大在 MCT 市場的份額,目前我們在 MCT 市場約佔 15% 的市場份額,而我們在長期心臟監測市場佔 72% 的市場份額。市佔率每提高 10 個百分點,每年可增加約 8,000 萬至 1 億美元的收入。

  • International markets continue to represent a compelling long-term growth opportunity. We are now commercial in the UK, select EU markets and Japan, markets that collectively conduct over 3 million ambulatory cardiac monitoring test annually and where iRhythm holds less than 1% share. In the UK, we delivered our largest quarter of volume ever and we'll be participating in pilots under the NHS Supply Chain's Value-based Procurement Program.

    國際市場仍代表著極具吸引力的長期成長機會。我們目前已在英國、部分歐盟市場和日本開展商業活動,這些市場每年合計進行超過 300 萬次動態心臟監測測試,而 iRhythm 在這些市場的份額不到 1%。在英國,我們實現了有史以來最大的季度交付量,我們將參與 NHS 供應鏈基於價值的採購計劃的試點項目。

  • In Japan, we are now generating in-country evidence to support future applications to the MHLW for reimbursement reconsideration. Across all regions, our focus remains on disciplined execution, evidence generation and Reimbursement progression as we scale these markets thoughtfully.

    在日本,我們目前正在收集國內證據,以支持未來向厚生勞動省提出的報銷重新考慮申請。在所有地區,我們將繼續專注於嚴謹的執行、證據的收集和報銷的推進,同時謹慎地擴大這些市場的規模。

  • We've also made encouraging progress with our Sleep Pilots. Early feedback continues to reaffirm the meaningful opportunity ahead as we address long-standing challenges in the sleep diagnostic market. With nearly 40 million sleep apnea patients in the US and significant overlap with arrhythmia populations, we believe we are well positioned to extend our workflow-driven model into this adjacent space as care continues to shift upstream.

    我們的睡眠試點計畫也取得了令人鼓舞的進展。早期回饋不斷印證了我們在解決睡眠診斷市場長期存在的挑戰方面所面臨的巨大機會。美國有近 4000 萬名睡眠呼吸中止症患者,並且與心律不整患者群體有很大的重疊,我們相信,隨著護理不斷向上游轉移,我們有能力將我們以工作流程為導向的模式擴展到這個相鄰的領域。

  • iRhythm today sits at the intersection of several powerful trends: an aging population, increasing prevalence of arrhythmias, movement toward value-based care and growing demand for proactive health management. We believe the market opportunity ahead is significantly larger than it has historically been viewed and that our platform spanning biosensors, AI and workflow, positions us well to lead that expansion.

    iRhythm 目前正處於幾個強大趨勢的交匯點:人口老化、心律不整盛行率增加、向價值導向醫療保健的轉變以及對積極健康管理的需求不斷增長。我們相信,未來的市場機會遠比以往所看到的要大得多,而我們涵蓋生物感測器、人工智慧和工作流程的平台,使我們能夠很好地引領這一擴張。

  • As we enter 2026, our focus is clear and consistent: one, delivered durable volume-led growth across cardiology, primary care and innovative channels. Two, expand margins through sustained operational efficiencies and scale benefits. Three, advanced platform innovation, including our next-generation MCT and predictive AI. Four, scale international and adjacent markets with discipline and rigor and, five, maintain operational excellence and compliance in a rapidly evolving health care environment. With this focus, we are confident in our ability to execute this expansion in a way that creates long-term value for patients, physicians, providers, payers and shareholders.

    進入 2026 年,我們的重點明確且一致:一、在心臟病學、初級保健和創新管道實現持久的、以銷售為導向的成長。第二,透過持續提高營運效率和規模效益來擴大利潤率。第三,先進的平台創新,包括我們的下一代MCT和預測性人工智慧。第四,以嚴謹的紀律和嚴格的作風拓展國際及鄰近市場;第五,在快速發展的醫療保健環境中保持卓越的運營和合規性。憑藉這一重點,我們有信心以一種能夠為患者、醫生、醫療服務提供者、支付方和股東創造長期價值的方式來執行此次擴張。

  • Finally, as the industry grapples with heightened scrutiny around medical documentation practices, including recent attention on chart scraping behaviors, we want to be explicit about our position. iRhythm operates as an independent diagnostic provider with objective clinically validated reports that integrate directly into provider workflows.

    最後,鑑於醫療產業正努力應對日益嚴格的醫療文件規範審查,包括近期對病歷抓取行為的關注,我們希望明確闡述我們的立場。 iRhythm 作為一家獨立的診斷服務提供者,提供客觀、經臨床驗證的報告,這些報告可直接整合到醫療服務提供者的工作流程中。

  • Our product is prescribed directly by a physician and enables a confirmatory diagnosis. Our processes are designed to support accurate diagnosis while reducing administrative burden and audit exposure for providers and payers. We are an effective tool providing exactly what oversight bodies are asking for in terms of confirmed diagnosis and are excited about the potential tailwinds from the emerging expectations of a more accountable, audit-sensitive environment.

    我們的產品由醫生直接開立處方,並可用於確診。我們的流程旨在支援準確診斷,同時減輕醫療服務提供者和支付方的行政負擔和審計風險。我們是一個有效的工具,能夠提供監管機構在確診方面所要求的確切信息,並且對日益增長的、更具問責制、更注重審計的環境所帶來的潛在利好感到興奮。

  • Thank you again for joining us today. 2026 marks iRhythm's 20th anniversary and represents a very important year as we aim to become a $1 billion company in 2027, whose truest measures are lives touched, innovations delivered and transformational leadership serving the patients who are counting on us.

    再次感謝您今天蒞臨。 2026年是iRhythm成立20週年,也是非常重要的一年,因為我們的目標是在2027年成為一家市值10億美元的公司。衡量我們成功的真正標準是:我們幫助了多少人,我們帶來了多少創新,以及我們以變革性的領導力服務於那些信賴我們的病人。

  • With that, I'll now turn the call over to Dan to walk through our financial results and outlook.

    接下來,我將把電話交給丹,讓他來介紹我們的財務表現和展望。

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Thank you, Quentin. iRhythm delivered continued strong financial performance in the fourth quarter and full year 2025, reflecting durable demand for iRhythm's Ambulatory Cardiac Monitoring Services and disciplined execution across the organization.

    謝謝你,昆汀。 iRhythm在2025年第四季和全年持續保持強勁的財務業績,這反映了市場對iRhythm動態心臟監測服務的持續需求以及公司各部門嚴謹的執行力。

  • We delivered fourth quarter 2025 revenue of $208.9 million representing 27.1% year over year growth and full year 2025 revenue of $747.1 million, representing 26.2% growth compared to 2024. Performance was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels. While volume remains the primary driver of growth, pricing was also favorable for full year 2025 and in the fourth quarter, including improvements with our estimated collections reserves related to our market access, contracting and collection efforts executed throughout 2025.

    我們實現了 2025 年第四季 2.089 億美元的收入,年增 27.1%;2025 年全年營收為 7.471 億美元,比 2024 年成長 26.2%。業績主要得益於客戶群持續的銷售需求,這反映了我們核心業務的持續強勁以及新興成長管道的貢獻。雖然銷售仍然是成長的主要驅動力,但 2025 年全年和第四季度的定價也較為有利,這包括我們預計的收款準備金的改善,這些準備金與我們在 2025 年全年執行的市場准入、合約簽訂和收款工作有關。

  • New store growth with new store defined as accounts that have been opened for less than 12 months accounted for approximately 68% of our year over year volume growth. Home enrollment for Zio Services in the US remained consistent from prior quarters, with approximately 23% of volume in the fourth quarter.

    新店成長(新店定義為開業不到 12 個月的帳戶)約占我們同比銷量成長的 68%。美國 Zio 服務的家庭註冊量與前幾季保持穩定,第四季註冊量約為 23%。

  • Moving down the P&L. Gross margin in the fourth quarter was 70.9%, an increase of 90 basis points year over year and full year gross margin was 70.6%, an improvement of 170 basis points year over year. This sustainable improvement was driven by continued operational efficiencies, including manufacturing automation and workflow optimization as well as scale benefits from higher volumes, partially offset by product mix.

    向下移動損益表。第四季毛利率為 70.9%,年增 90 個基點;全年毛利率為 70.6%,較去年同期成長 170 個基點。這項永續改善得益於持續的營運效率提升,包括製造自動化和工作流程最佳化,以及產量增加帶來的規模效益,但部分被產品組合所抵銷。

  • Fourth quarter operating expenses were $145.8 million compared to $119.2 million in the prior year period, and operating expenses for the full year 2025 were $584.7 million, an increase of 11.8%. We invested purposefully in the business to fuel near, mid- and long-term growth while delivering strong operating leverage with revenue growing meaningfully faster than operating expenses.

    第四季營運支出為 1.458 億美元,而上年同期為 1.192 億美元;2025 年全年營運支出為 5.847 億美元,成長 11.8%。我們有目的地對業務進行投資,以推動近期、中期和長期成長,同時實現強勁的營運槓桿,營收成長速度明顯快於營運支出。

  • On the bottom line, net income for the fourth quarter was $5.6 million or $0.17 per diluted share and was the first positive quarterly net income in iRhythm's history. Net loss for the full year 2025 was $44.6 million or a loss of $1.39 per diluted share. Adjusted EBITDA for the fourth quarter was $34.3 million or 16.4% of revenue, representing a 470 basis points improvement year over year and a significant improvement in profitability.

    最終,第四季淨利潤為 560 萬美元,即每股攤薄收益 0.17 美元,這是 iRhythm 公司歷史上首次實現季度淨利潤為正。2025 年全年淨虧損為 4,460 萬美元,即每股攤薄虧損 1.39 美元。第四季調整後 EBITDA 為 3,430 萬美元,佔營收的 16.4%,較去年同期成長 470 個基點,獲利能力顯著提高。

  • Full year adjusted EBITDA was $68.9 million or 9.2% of revenue, representing an improvement of more than 1,000 basis points compared to 2024 and over 500 basis points if normalizing for IP R&D expenses. We generated $14.5 million of free cash flow in the fourth quarter and $34.5 million for the full year, ending 2025 with $583.8 million in cash, cash equivalents and marketable securities and providing us with substantial flexibility to support future growth initiatives.

    全年調整後 EBITDA 為 6,890 萬美元,佔營收的 9.2%,與 2024 年相比提高了 1,000 多個基點,如果扣除智慧財產權研發費用,則提高了 500 多個基點。我們在第四季度產生了 1,450 萬美元的自由現金流,全年產生了 3,450 萬美元的自由現金流,到 2025 年底,我們擁有 5.838 億美元的現金、現金等價物和有價證券,這為我們提供了相當大的靈活性來支持未來的成長計畫。

  • And another milestone for iRhythm, 2025 was the first year of positive adjusted EBITDA and free cash flow in the company's history. A significant result for the company and demonstrative of the profitable growth we are focused on delivering. Looking ahead, we entered 2026 with strong momentum and a solid foundation. For the full year 2026, we expect revenue to be in the range of $870 million to $880 million, representing 16% to 18% year over year growth.

    對 iRhythm 而言,2025 年是另一個里程碑,也是該公司歷史上首次實現調整後 EBITDA 和自由現金流為正的一年。這對公司來說是一個重要的成果,也反映了我們所致力於實現的獲利成長。展望未來,我們帶著強勁的發展勢頭和堅實的基礎進入了2026年。我們預計 2026 年全年營收將在 8.7 億美元至 8.8 億美元之間,年增 16% 至 18%。

  • This outlook reflects sustained demand across our core business while maintaining a disciplined approach to forecasting newer and emerging channels. On a full year basis, we expect pricing to be approximately flat overall to 2025, with revenue growth driven by continued volume growth across core Zio Monitor, Zio AT, innovative channel and international.

    這個前景反映了我們核心業務的持續需求,同時我們也保持了對新興通路預測的嚴謹態度。從全年來看,我們預計到 2025 年,價格總體上將保持平穩,收入成長將由核心 Zio Monitor、Zio AT、創新通路和國際市場的持續銷售成長所推動。

  • In the first quarter of 2026, we anticipate revenue to be in the range of $193 million to $195 million, consistent with typical revenue seasonality. For gross margin, we expect the clinical operations and manufacturing efficiencies we've driven will continue to incrementally improve our gross margin profile for the full year 2026. We believe that these sustainable improvements will continue to lower our cost to serve as we leverage our fixed cost infrastructure over a higher volume of patients overtime and introduce new artificial intelligence and workflow tools.

    我們預計 2026 年第一季的營收將在 1.93 億至 1.95 億美元之間,與典型的營收季節性一致。對於毛利率而言,我們預計我們所推動的臨床營運和生產效率將繼續逐步提高我們 2026 年全年的毛利率水準。我們相信,隨著我們利用固定成本基礎設施服務更多患者,並引入新的人工智慧和工作流程工具,這些可持續的改進將繼續降低我們的服務成本。

  • From a profitability standpoint, we expect adjusted EBITDA margin to expand meaningfully to 11.5% to 12.5% of revenue in 2026, reflecting continued gross margin improvement and operating leverage while still investing appropriately in product innovation, commercial initiatives, international expansion and platform capabilities.

    從獲利能力的角度來看,我們預計到 2026 年,調整後的 EBITDA 利潤率將顯著提高至收入的 11.5% 至 12.5%,這反映了毛利率的持續改善和營運槓桿作用,同時我們仍在對產品創新、商業舉措、國際擴張和平台能力進行適當的投資。

  • We continue to anticipate normal seasonality in our adjusted operating expense profile with higher expenses coming through in the earlier half of the year due to spend associated with corporate activities and payroll expenses. For the first quarter of 2026, we anticipate adjusted EBITDA margin to be between 3% and 4% of revenue. And lastly, we expect free cash flow to grow versus 2025 with free cash flow more heavily weighted in the second half of the year due to normal operating seasonality.

    我們預計調整後的營運費用結構將呈現正常的季節性變化,上半年由於與公司活動和工資相關的支出,費用將會增加。我們預計 2026 年第一季調整後的 EBITDA 利潤率將佔營收的 3% 至 4%。最後,我們預計自由現金流將比 2025 年有所成長,由於正常的經營季節性因素,自由現金流在下半年的佔比會更高。

  • In closing, we delivered a strong fourth quarter and a transformational year in 2025. We exited the year profitably, free cash flow positive and well positioned to continue scaling the business. Our financial performance reflects the durability of our growth model, the leverage in our operating structure and the discipline in which we are investing for the future. We believe our improving financial profile is supported not only by operating leverage, but also by the growing recognition that our services can reduce downstream health care utilization, which supports durable demand and efficiency-focused care environments.

    最後,我們實現了強勁的第四季業績,並展望了具有變革意義的 2025 年。我們以獲利結束了這一年,自由現金流為正,並已做好充分準備繼續擴大業務規模。我們的財務表現反映了我們成長模式的持久性、我們營運結構的槓桿作用以及我們為未來投資所秉持的嚴謹態度。我們相信,我們不斷改善的財務狀況不僅得益於經營槓桿,還得益於人們越來越認識到我們的服務可以減少下游醫療保健的使用,從而支持持久的需求和以效率為中心的護理環境。

  • I will now turn the call back to Quentin for closing remarks.

    現在我將把電話轉回給昆汀,請他作總結發言。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • The fourth quarter capped an exceptional year for iRhythm. In 2025, we delivered strong top line growth, expanded margins and achieve profitability and free cash flow positivity for the first time in our company's history, all while continuing to invest in innovation and long-term growth. At its core, the challenge in arrhythmia detection remains clear, a reactive symptom-driven approach continues to miss patients. Arrhythmias are episodic, often asymptomatic and frequently undetected by short duration diagnostics, leaving millions undiagnosed and contributing to avoidable downstream events. At the same time, access constraints across the health care system are intensifying, with nearly half of US counties lacking a cardiologist, the point of detection must move upstream.

    第四季為iRhythm公司卓越的一年畫上了圓滿的句點。2025年,我們實現了強勁的營收成長,擴大了利潤率,並在公司歷史上首次實現了盈利和自由現金流為正,同時繼續投資於創新和長期成長。從本質上講,心律不整檢測面臨的挑戰仍然很明確,被動的症狀驅動方法仍然會漏診患者。心律不整是間歇性的,通常沒有症狀,而且經常無法透過短時診斷發現,導致數百萬人未被診斷,並造成可避免的後續事件。同時,醫療保健系統的准入限制日益加劇,美國近一半的縣沒有心臟科醫生,因此,檢測點必須轉移到上游。

  • We believe these forces, rising clinical need and constrained access are fundamentally reshaping our market and play directly into iRhythms' strengths. As we enter 2026, our 20 year as a company, we do so with more momentum, scale and strategic clarity than at any point in our history. Looking ahead to 2026, we are confident in our ability to deliver another year of durable volume-led growth while continuing to expand profitability.

    我們認為,不斷增長的臨床需求和受限的准入正在從根本上重塑我們的市場,並直接發揮 iRhythms 的優勢。2026 年是我們公司成立 20 週年之際,我們比以往任何時候都擁有更強的發展動能、更大的規模和更清晰的策略方向。展望 2026 年,我們有信心在繼續擴大獲利能力的同時,實現另一個銷售持續成長的年份。

  • Our focus remains on disciplined execution, expanding access through primary care and integrated networks, advancing our platform through AI and workflow innovation and investing selectively in product and international growth, all while maintaining financial discipline. We believe iRhythm is still in the early innings of unlocking a market that is far larger than historically recognized, and we are well positioned to lead that expansion in a way that creates long-term value for patients, providers, payers and shareholders.

    我們將繼續專注於嚴謹的執行,透過初級保健和綜合網路擴大服務範圍,透過人工智慧和工作流程創新來推進我們的平台,並選擇性地投資於產品和國際成長,同時保持財務紀律。我們相信 iRhythm 仍處於開拓市場的初期階段,而這個市場遠比歷史上所認識到的要大得多,我們有能力引領這一擴張,從而為患者、醫療服務提供者、支付方和股東創造長期價值。

  • With that, we're now happy to take your questions.

    那麼,現在我們很樂意回答您的問題。

  • Operator

    Operator

  • (Operator Instructions)

    (操作說明)

  • Joanne Wuensch, Citi Group.

    Joanne Wuensch,花旗集團。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • I think part of what has been weighing on the stock is the language around the elimination of chart-derived diagnosis from CMS and what it might mean for Zio use? Could you please address that? And I do have a follow-up.

    我認為對該股造成壓力的部分原因是有關取消 CMS 圖表診斷的措辭,以及這可能對 Zio 使用產生的影響?請問您能解答一下這個問題嗎?我還有一個後續問題。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Joanne, thanks for being here. Thanks for the question. Yeah, I'd be happy to address that. I think that -- actually, I think there's two issues in and around Medicare to address. One is around the pricing and one is around the chart-derived diagnosis.

    喬安妮,謝謝你來。謝謝你的提問。是的,我很樂意回答這個問題。我認為——實際上,我認為醫療保險領域內外有兩個問題需要解決。一個問題與定價有關,另一個問題與圖表診斷有關。

  • And I think that Zio frankly fits both of those issues really well in terms of addressing the underlying concerns that might be out there around it. When you think about chart-drive diagnosis, Zio delivers the opportunity to get to a confirmatory diagnosis, which I think is very important. Physicians are prescribing the product. Patients are wearing that product. We're getting a very clear signal from that patient of which we're then able to provide a report that can provide an opportunity for that physician to confirm a diagnosis.

    坦白說,我認為 Zio 在解決可能的潛在擔憂方面,確實很好地契合了這兩個問題。當你考慮基於圖表的診斷時,Zio 提供了獲得確診的機會,我認為這非常重要。醫生正在開立該產品的處方。患者正在使用該產品。我們從這位患者那裡得到了非常清晰的信號,然後我們能夠提供一份報告,讓醫生有機會確認診斷。

  • And I think that's very important that it ends up integrating into the workflow and the patient records, that are then ultimately reviewed down the line from an audit perspective or any other perspective to confirm, in fact, that there was a diagnosis made.

    我認為非常重要的一點是,最終將其整合到工作流程和患者記錄中,然後從審計或其他任何角度進行審查,以確認是否確實做出了診斷。

  • So I think we play very well there. I'm actually very excited by some of the conversations we've had with partners out there who are using the device in that way, and I believe it's going up being a nice tailwind for us. At the same time, I think there's some concerns around just the overall pricing direction, maybe pricing not intended to be as much of an increase in the future years is what folks had anticipated.

    所以我覺得我們在那裡發揮得非常好。實際上,我們與一些以這種方式使用該設備的合作夥伴進行了一些交流,這讓我感到非常興奮,我相信這將為我們帶來良好的發展勢頭。同時,我認為人們對整體定價方向存在一些擔憂,也許未來幾年價格不會像人們預期的那樣大幅上漲。

  • But I think, again, what we're finding in these programs that Zio is being utilized and is that we are, in fact, reducing the cost of care for these patients and that's starting to become very clear to us. I actually think you're going to see some data that's going to get published later this year from some of these innovative channel partners who are able to demonstrate pretty clearly now that they've got a period of time under their belt of using Zio in a proactive way that is going to demonstrate the cost of caring for these populations is in fact being reduced and coming down.

    但我認為,我們再次發現,在這些項目中,Zio 正在被使用,而且我們實際上正在降低這些患者的護理成本,這一點我們越來越清楚地認識到。我認為今年晚些時候,一些創新通路合作夥伴將會公佈一些數據,這些數據能夠非常清楚地表明,他們已經積極主動地使用 Zio 一段時間,這將證明照顧這些人群的成本實際上正在降低。

  • And that's exciting to see. I can't wait to have that data get published and get out there, but I think it addresses the very focus of where health care is going, which is we've got to get the cost of care down and Zio is demonstrating the real ability to do that. So I think both of those have been a bit of an area of concern, and I think Zio and iRhythm itself are positioned incredibly well to address those.

    看到這一幕真是令人興奮。我迫不及待地想看到這些數據公佈並傳播出去,但我認為這正切中了醫療保健發展方向的核心問題,那就是我們必須降低醫療成本,而 Zio 正在展現出實現這一目標的真正能力。所以我認為這兩個方面都有些令人擔憂,而我認為 Zio 和 iRhythm 本身已經做好了充分的準備來解決這些問題。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • Just as a quick follow-up and a different topic. Could you give guidance for what you think gross and operating margins may look like for 2026?

    簡單補充一下,換個話題。您能否預測2026年的毛利率和營業利率會是什麼樣子?

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Yeah. Joanne, we did give formal guidance for adjusted EBITDA. That was adjusted EBITDA margin of 11.5% to 12.5% for the full year. We also gave guidance there for Q1 of 3% to 4% for Q1 '26. On gross margin, I did comment, we expect incremental improvement relative to 2025, I can tell you we're thinking that in the range of 80 to 100 basis points of improvement relative to 2025. So hopefully, that gets you there for the '26 number.

    是的。Joanne,我們確實給出了調整後 EBITDA 的正式預期。全年調整後 EBITDA 利潤率為 11.5% 至 12.5%。我們也給出了 2026 年第一季 3% 至 4% 的業績預期。關於毛利率,我之前評論過,我們預計相對於 2025 年會有逐步改善,我可以告訴你,我們認為相對於 2025 年會有 80 到 100 個基點的改善。希望這樣能幫你找出 '26' 這個數字。

  • Operator

    Operator

  • (Operator Instructions)

    (操作說明)

  • Vijay Kumar, Evercore ISI.

    Vijay Kumar,Evercore ISI。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • One on the guidance kind of questions, right. Look, I know this focus on CMS reimbursement. But I'm wondering, is the CMS proposal perhaps a tailwind if hospitals are doing chart-scrapping are they now being forced to use or should be using Zio Monitor in LTCM patches, right, to avoid chart-scrapping. So I'm wondering, could this be a tailwind and along those lines, what are you assuming for international growth in fiscal '26?

    其中一個是關於指導性問題,對吧。我知道大家都很關注 CMS 的報銷問題。但我很好奇,如果醫院正在進行病歷抓取,CMS 的提議是否可能是有利因素?他們現在是否被迫或應該在 LTCM 補丁中使用 Zio Monitor,以避免病歷抓取?所以我想知道,這是否會成為順風?基於此,您對 2026 財年的國際成長有何預期?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Thank. Maybe I'll let Dan hit on the international assumption in the guidance. With respect to your first question, and the chart-scraping comments and again, having a confirmatory diagnosis that is in the medical records. I think that is something that our partners are very focused on, again, in the discussions with them, I think that's exactly the path that they're heading down. I'm bullish on what that has the potential to mean for iRhythm in our company.

    感謝。或許我可以讓丹來談談指導意見中的國際假設。關於你的第一個問題,以及關於圖表抓取的評論,還有再次強調,需要在醫療記錄中找到確診資訊。我認為這是我們的合作夥伴非常關注的事情,在與他們的討論中,我認為這正是他們正在努力的方向。我非常看好 iRhythm 在我們公司可能帶來的發展前景。

  • I do think that while they're going to look for ways to continue to button up and bolster sort of their evidence and documentation around anything with particular Medicare focus on it. And so I do think this ends up being a tailwind.

    我認為他們會想辦法繼續改進和加強與醫療保險相關的任何證據和文件。所以我認為這最終會成為一股順風。

  • At the same time, we did not factor anything into our forward-looking expectations around this at this point in time. I think this is one where we'll let that play out. We'll let that show up in results. And if so, we'll talk about that in a very favorable way. But early indications, early conversations, I feel -- feel very bullish around sort of how folks are talking about the way that iRhythm and Zio can be used to address some of these concerns. We'll see how that plays but I'm excited about it. Dan, maybe you want to hit on the international.

    同時,目前我們並未將此因素納入我們對未來的預期之中。我認為這件事就讓它順其自然吧。我們會讓這個結果顯示出來。如果真是這樣,我們會以非常積極的方式討論這件事。但從早期的跡象和早期的討論來看,我對人們談論 iRhythm 和 Zio 可以用來解決其中一些問題的方式感到非常樂觀。我們拭目以待,但我很期待。丹,或許你想嘗試國際賽。

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Yeah. Vijay, so a question on international contribution within the 2026 guide. We'll tell you that we have that growing slightly ahead of overall company growth. I would say some upside there potentially, but really just getting started in a number of those markets, five of the six that we are in, were opened, call it, in the last 18 months or so. So would expect the progress we're making in '26 to really show up more meaningfully in terms of contribution as we look to '27 and beyond.

    是的。Vijay,那麼關於2026年指南中的國際貢獻,請問一個問題。我們會告訴你,我們的成長速度略高於公司整體成長速度。我認為那裡可能有一些上漲空間,但實際上我們才剛開始涉足其中的幾個市場,我們進入的六個市場中有五個都是在過去 18 個月左右才開設的。因此,我們預計我們在 2026 年取得的進展將在 2027 年及以後的貢獻方面真正得到更有意義的體現。

  • Operator

    Operator

  • Allen Gong, JPMorgan.

    Allen Gong,摩根大通。

  • Allen Gong - Analyst

    Allen Gong - Analyst

  • Thanks for the question. So let me get one, and I kind of want to touch on some of the AI concerns that we've seen weighing on some stocks in med tech recently. I think in the past, you've talked about maybe like 20% of the customer base will want to -- want to be some of the analysis on their own. And in that case, you're not really able to build CMS for that analysis portion of the code. But if your providers are more willing to use AI and potentially do some of that analysis on their own with the help of third-party providers. Is that something that you're concerned about? And how do you address that concern?

    謝謝你的提問。讓我先說一下,我想談談最近一些醫療科技股票因人工智慧問題而承壓的一些情況。我認為你過去曾說過,大約 20% 的客戶群會希望——希望自己進行一些分析。在這種情況下,您實際上無法為程式碼的分析部分建立內容管理系統 (CMS)。但如果你的供應商更願意使用人工智慧,並且可能在第三方供應商的幫助下自行進行一些分析。你擔心的是這件事嗎?那麼,您如何解決這個問題?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Thanks, Allen. Look, I think we're all incredibly excited about the prospects of AI and where that can go over the future years. I think at the same time, we've been doing this for 20 years. And frankly, our platform is pretty much a closed platform. But I think what sets us apart and continues to give me confidence that we're going to have success in this area is that it's more than just a software capability. It's more than just an AI capability. It starts with the data. The AI is only as good as the data coming into it. And we have very specific purpose-built hardware that allows us to capture very clean ECG data, having a clean signal is very important.

    謝謝你,艾倫。你看,我認為我們都對人工智慧的前景以及它在未來幾年可能的發展方向感到無比興奮。我認為同時,我們已經做了20年了。坦白說,我們的平台基本上是一個封閉的平台。但我認為,真正讓我們脫穎而出,並讓我持續相信我們在這個領域會成功的,是它不僅僅是一種軟體能力。這不僅僅是人工智慧能力。一切從數據開始。人工智慧的效能取決於輸入資料的品質。我們有專門設計的硬件,可以擷取非常清晰的心電圖數據,獲得清晰的訊號非常重要。

  • If you're starting to bring together disparate data sets, ECG data that are very unique and different and marked in different ways. I think it's hard for that AI to truly be specific and as good as what iRhythm is able to generate and provide. You also have to keep in mind, we operate in a very highly regulated space where each of these algorithms require FDA clearance. And that clearance takes years and years of clinical validation. It takes real-world evidence, things that are measured in time frames of years, not months or quarters.

    如果您開始將不同的資料集整合在一起,例如非常獨特、各不相同且以不同方式標記的心電圖資料。我認為人工智慧很難真正做到像 iRhythm 一樣精準、有效率地產生和提供資訊。您還必須記住,我們身處一個監管非常嚴格的領域,其中每種演算法都需要獲得 FDA 的批准。而獲得批准需要經過多年的臨床驗證。這需要現實世界的證據,需要以年為單位來衡量,而不是以月或季為單位。

  • There's work to be done in and around reimbursement and workflow as well that become major barriers. You look at our past. We've done the work to establish the CPT codes. We've got CMS coverage in place, national coverage decisions. We've got commercial payer contracts that are in place and importantly, I think, deep EHR integrations.

    在報銷和工作流程方面也存在著許多需要改進的地方,這些都成為了主要的障礙。看看我們的過去。我們已經完成了CPT代碼的製定工作。我們已經落實了CMS的健保覆蓋範圍,並做出了全國性的健保覆蓋決定。我們已經與商業支付方簽訂了合同,而且我認為更重要的是,我們實現了深度電子病歷整合。

  • Physicians don't just simply adopt algorithms and they're not going to just simply bolt-on a bunch of AI algorithmic capabilities onto their existing platforms. It has to fit within their workflow. And I think that's something that we continue to build out and have a tremendous focus on. We've commented on this in the past, over half of our volumes flow through integrated systems with our customers. And I think that ends up being a very important aspect of how AI will continue to get introduced into the future.

    醫生不會輕易接受演算法,也不會簡單地將一堆人工智慧演算法功能添加到他們現有的平台上。它必須符合他們的工作流程。我認為這是我們將繼續努力發展並重點關注的領域。我們過去曾評論過這一點,我們超過一半的業務量都是透過與客戶的整合系統進行的。我認為這最終將成為人工智慧未來發展方式中一個非常重要的方面。

  • And then just given the size, and we've got 13 million patients, we got 3 billion hours. That data set is growing incredibly fast, which is going to give us the ability to stay ahead from an AI perspective. So I feel really good about our opportunity to continue to have success here and protect the business but also grow it really, really well and frankly, even take advantage of the platform that we have, where we can drop in other AI capabilities as we go into the future that I think allows us to be unique and differentiated. So I like our position here, and I feel good about it, and I think we're in a unique spot here.

    考慮到醫院的規模,我們有 1300 萬名患者,我們有 30 億小時。該資料集成長速度驚人,這將使我們能夠在人工智慧領域保持領先地位。因此,我對我們繼續在這裡取得成功並保護業務,同時實現業務的蓬勃發展感到非常樂觀。坦白說,我們甚至可以利用我們現有的平台,在未來逐步引入其他人工智慧功能,我認為這將使我們變得獨特和與眾不同。所以我很滿意我們目前的處境,感覺很好,我認為我們正處於一個獨特的位置。

  • Operator

    Operator

  • Richard Newitter, Truist.

    Richard Newitter,Truist。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • I wanted to just ask on MCT. I know it sounds like that's going to -- you guys are committing -- or recommitting to that coming commercial in the first half '27, to hear that. I guess can you just run through what exactly you need to do to get that over the finish line? At the JP Morgan conference, you talked through some enhancements and feature sets that you're going to integrate into it. Can you just remind us what those are, what's involved there and the confidence in the timeline?

    我只是想在MCT上問問。我知道這聽起來像是——你們要承諾——或者重新承諾在 2027 年上半年推出那條廣告。我想請你詳細說明一下,為了完成這件事,你需要做些什麼?在摩根大通大會上,您詳細介紹了您將要整合到其中的一些增強功能和特性集。您能簡單提醒一下這些是什麼,涉及哪些方面,以及對時間表的信心如何嗎?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah. Look, nobody is more excited about MCT than we are. I can tell you that as well as our commercial team and even our customers. I think we're in a great spot right now. Clearly, Zio AT is performing incredibly well. I think it's demonstrating the ability to be very sustainable and durable in terms of its growth profile. We're now over a year of growth with that product line that is more than twice the rate of our total company. And in Q4, it was up sequentially another 10%. So the momentum in AT affords us to make some decisions in and around MCT that are in the right path for the long-term outcomes of the company versus the short-term speed, but there are some things we could do to bring it to market faster. But frankly, it's not the right thing to do.

    是的。瞧,沒有人比我們更興奮於MCT(中鏈三酸甘油酯)。我可以告訴你這一點,我們的銷售團隊甚至我們的客戶也都認同這一點。我認為我們現在處境非常好。顯然,Zio AT 的表現非常出色。我認為這表明,就其成長前景而言,它具有很強的可持續性和持久性。該產品線至今已成長一年多,其成長速度是公司整體成長速度的兩倍多。第四季度,季增了10%。因此,AT 的發展勢頭使我們能夠在 MCT 及其相關領域做出一些決策,這些決策更有利於公司的長期發展,而不是追求短期速度,但我們也可以做一些事情來更快地將其推向市場。但坦白說,這樣做並不合適。

  • And this is a category that's evolved quite a bit over the last two years with the FDA in terms of their expectations as well as future expectations, including even a new category code that was created within the last couple of years as well. And so I think we understand with the FDA, with future expectations are going. And one of the most notable improvements that we need to make or changes that we need to make to to our MCT submission, frankly, is getting to a mobile gateway, moving away from our old gateway that's been out there for well over a decade and going ahead and making that move to a mobile gateway today, is important. That's something that we're in discussions with the FDA on right now in terms of how to update the submission. And so we're moving down that pathway and MCT will come to market with a new gateway.

    過去兩年,隨著 FDA 對其預期和未來預期的調整,這個類別已經發生了相當大的變化,甚至在最近幾年還創建了一個新的類別代碼。所以我認為我們和FDA都理解,未來的預期是這樣的。坦白說,我們需要對 MCT 提交進行的最顯著的改進或改變之一,就是採用行動網關,擺脫我們已經使用了十多年的舊網關,今天就轉向行動網關,這非常重要。目前我們正在與FDA討論如何更新提交資料。因此,我們將沿著這條道路前進,MCT 將透過新的管道進入市場。

  • We continue to feel confident in that first half of '27 time frame, and that's the right way to think about it, excitingly, it's going to get our duration out beyond 14 days, get us to 21 days. It's going to have an enhanced algorithmic capability with it as well. With the mobile gateway, it's actually going to improve the patient's interaction and experience quite a bit, which is exciting to see as well. So better cost economics, better cost profile, better impact on gross margin over time. These are all things that are in the right long-term health of our business, and we're pursuing to be in a position where we can make those decisions versus speed to market. So feel good about it. We're excited to get MCT to market, and we're just working with the FDA now on the best way to get that done.

    我們仍然對 2027 年上半年的時間框架充滿信心,而且這種想法是正確的,令人興奮的是,這將使我們的持續時間超過 14 天,達到 21 天。它還將具備更強大的演算法能力。行動網關的引入,實際上將大大改善患者的互動和體驗,這令人非常興奮。因此,成本效益更高,成本結構更優,隨著時間的推移,對毛利率的影響也更大。這些都是對我們業務的長期健康發展至關重要的因素,我們正在努力讓自己處於能夠做出這些決策而不是追求上市速度的位置。所以,別為此感到遺憾。我們很高興能將MCT推向市場,現在我們正在與FDA合作,尋找實現這一目標的最佳途徑。

  • Operator

    Operator

  • Brandon Vazquez, William Blair.

    布蘭登·瓦茲奎茲,威廉·布萊爾。

  • Brandon Vazquez - Analyst

    Brandon Vazquez - Analyst

  • Maybe, Dan, for you, I wanted to go back to guidance real quick. I think you used the phrase disciplined approach to forecasting when you gave the guidance. Maybe sub talk to us a little bit about what that means, what it is, what is embedded, what are the risks and opportunities as you think about the 2026 guidance frame that you gave us?

    丹,或許,我想快速地回到指導環節。我認為你在給出指導意見時使用了“嚴謹的預測方法”這個短語。或許您可以稍微跟我們談談這意味著什麼,它是什麼,其中包含什麼,以及在您考慮您給出的 2026 年指導框架時,存在哪些風險和機會?

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Thanks, Brandon, for the question. So maybe we'll just start. No change to kind of our philosophy on guidance. We want to be thoughtful. We want to put something out there that we're confident that we can deliver. And as you've heard us talk about a few times now, leave some of the upside opportunities out of the guide that ultimately, if they do play through, we'll be happy and can over-deliver on that initial guidance.

    謝謝布蘭登的提問。所以,或許我們就此開始吧。我們的指導理念基本上沒有改變。我們希望考慮周全。我們希望推出我們有信心能夠交付的產品。正如我們之前多次提到的,我們將一些潛在的上漲機會排除在業績指引之外,但最終,如果這些機會真的發生,我們會很高興,並且能夠超越最初的業績指引。

  • In terms of kind of the different areas of contribution within that guidance, maybe starting with core U.S. monitor continue to -- that continues to fuel the majority of our growth from an absolute dollar standpoint. We're growing in line with the market, if not a bit faster than the market. We're seeing primary care continue to expand the opportunity and then certainly our remaining opportunity to continue to shift share away from legacy technology. So feel really good about kind of the durable growth there. That was a source of upside in '25, the core US monitor that there's an opportunity for that in '26 as well.

    就該指導方針中不同的貢獻領域而言,或許可以從核心的美國監測繼續說起——從絕對美元的角度來看,這繼續推動著我們大部分的成長。我們的成長與市場同步,甚至可能比市場略快。我們看到初級保健領域的機會不斷擴大,當然,我們還有機會繼續將市場份額從傳統技術轉移出去。所以我對這種持續成長感到非常滿意。這是 2025 年上漲的來源,美國核心監測機構認為 2026 年也有這樣的機會。

  • With Zio AT, you heard Quentin talk about momentum and the strength that we're seeing there. Certainly an opportunity to continue to grow our share of that segment, right, from the 15% we are today, and we're really winning kind of alongside to Zio Monitor and winning kind of as a full platform. So really encouraged what we're seeing with AT.

    在談到 Zio AT 時,你聽 Quentin 談到了發展勢頭以及我們目前看到的強勁勢頭。當然,這是一個繼續擴大我們在該細分市場份額的機會,對吧?我們目前的份額是 15%,而且我們確實在與 Zio Monitor 並肩作戰,作為一個完整的平台而取得成功。看到AT的成就,我真的非常鼓舞。

  • In '25, you did hear Quentin comment, AT was growing essentially double the company average. That isn't -- what was contemplated in the '26 guidance, really think about AT growing a bit ahead of overall company growth, but below that double company average that we saw in 2025. And then the last component I mentioned -- I talked about international earlier. The last component being innovation -- innovative channel. So continue to expect that to remain the fastest-growing channel.

    2025年,昆汀曾評論說,AT的成長速度基本上是公司平均值的兩倍。那不是——在 2026 年的業績指引中設想的那樣,實際上,AT 的成長速度會略高於公司整體成長速度,但低於我們在 2025 年看到的公司平均值的兩倍。最後,我提到的最後一個組成部分——我之前談到了國際化。最後一個組成部分是創新——創新管道。因此,預計它仍將是成長最快的管道。

  • What's baked into guidance is really just an incremental step-up from the run rate that we saw exiting 2025. So the run rate in Q4. If you were to annualize that, that gets you to the majority of what we've contemplated in guidance and continue to feel good about delivering that. Certainly, some upside in that channel. It's a newer part of our business, a little bit less visibility than the core business.

    指導意見中實際上只是在2025年底之前的增長速度基礎上略有提高。所以第四季的運行率。如果將這些數字按年計算,就能達到我們在指導意見中考慮的大部分內容,並且我們仍然有信心實現這些目標。當然,這個通路還有一些上漲空間。這是我們業務中比較新的部分,與核心業務相比,知名度稍低。

  • We want to be really thoughtful around what we baked in the guidance there. We did have some incremental partners come in, in Q4 and Q1, which puts us in a really good position to continue to grow that part of the business. So hopefully, that helps then kind of deconstruct the '26 guidance.

    我們希望認真思考我們在指導方針中融入的內容。我們在第四季和第一季確實新增了一些合作夥伴,這使我們處於非常有利的地位,可以繼續發展這部分業務。希望這有助於對 2026 年的指導方針進行一些分析。

  • Operator

    Operator

  • Marie Thibault, BTIG.

    瑪麗·蒂博,BTIG。

  • Marie Thibault - Analyst

    Marie Thibault - Analyst

  • Just wanted to follow up on that question about guidance and try to see if we could learn a little bit more about what's being included in that outlook for the partnership. I wonder if you could just tell us a little bit more about the number of partners you now have that you're working with? How many might be scaling up this year after pilots last year. Any more detail in all of the focus of interest for us.

    我只是想就指導方針的問題做個後續說明,看看我們能否更了解一下合作關係展望中包含哪些內容。我想請您詳細介紹一下您目前合作的合作夥伴數量?繼去年的試點計畫之後,今年可能會有多少公司擴大規模?任何關於我們關注焦點的更多細節。

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Yeah. Thank you, Marie. So I would say we -- as I just mentioned, we continue to add partners to that part of the business, the Innovative Channel business. I will tell you it will start to -- has started to blur with the core part of our business as these partners are monitoring both symptomatic and asymptomatic patients. So in terms of the number of absolute partners, we're likely not to give that kind of quarter-to-quarter, but I did mention, we've added incremental partners both in Q4 and the early part of Q1. So I feel good about where that business is headed. It's early. It's an emerging part of our business. So as we think about setting up guidance really want to make sure we're not getting ahead of ourselves there.

    是的。謝謝你,瑪麗。所以我想說,正如我剛才提到的,我們將繼續為創新通路業務這部分增加合作夥伴。我要告訴你的是,這種情況將會開始——並且已經開始與我們業務的核心部分變得模糊不清,因為這些合作夥伴正在監測有症狀和無症狀的患者。因此,就絕對合作夥伴的數量而言,我們可能不會給出季度間的相應數據,但我確實提到過,我們在第四季度和第一季初都增加了新的合作夥伴。所以我對這家公司的發展方向感到樂觀。現在還早。這是我們業務中一個新興的部分。所以,當我們考慮制定指導方針時,我們真的想確保我們不會操之過急。

  • Operator

    Operator

  • Nathan Treybeck, Wells Fargo.

    內森·特雷貝克,富國銀行。

  • Nathan Treybeck - Equity Analyst

    Nathan Treybeck - Equity Analyst

  • So Quentin, just kind of as you mentioned in this quarter, you were operating a compositive. You hit 16% EBITDA margin at an annualized revenue that's below $1 billion. I guess, when can we expect you to refresh your LRP targets? And it seems like there could be pretty significant upside to those LRP targets considering that you still have remediation costs, your cost base. And Dan, just on the OpEx, it came in considerably below my forecast, I just want to understand what's going on there? And how should we think about OpEx in '26?

    所以昆汀,就像你在本季提到的那樣,你當時正在經營一家複合型企業。年化收入低於 10 億美元,卻實現了 16% 的 EBITDA 利潤率。我想問一下,你們什麼時候會更新LRP目標?考慮到你仍然需要承擔補救成本和成本基礎,這些 LRP 目標似乎可能有相當大的上漲空間。丹,就營運支出而言,實際支出遠低於我的預期,我只是想了解一下這是怎麼回事?那麼,我們該如何看待2026年的營運支出呢?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah. Maybe I'll hit on the $1 billion and the long-range plan. I think as we get close to that in '27, certainly, Nathan, we'll take a look at refreshing what that looks like further out in the future. But look, we're going to deliver on what we said we were going to do. And as we get close to doing that, then that's going to make the right sort of sense in terms of time to reset some expectations.

    是的。或許我能找到10億美元的資金和長期計畫。我認為,隨著 2027 年的臨近,內森,我們肯定會考慮在未來更遠的時間內重新審視它的樣子。但是,我們一定會兌現我們承諾的事情。當我們接近實現這一目標時,從時間角度來看,重新調整一些預期就顯得合理了。

  • I do feel very good about it. You think back four years ago, almost when we set that expectation. Certainly, a lot of things played out very differently than what we anticipated. We thought we would have had the MCT product here, frankly, a couple of years ago. But to see the way the team has been able to really drive the core business and what we've seen in our core Monitor business, what we've opened up in the innovative channel partners, what we are seeing in that MCT category, even without -- what we think is a much better product in the new MCT offering. We know that, that market share opportunity is real.

    我對此感覺非常好。回想一下四年前,我們幾乎就是在那時設定了那個預期。當然,很多事情的發展都和我們預想的截然不同。坦白說,我們原本以為幾年前就能在這裡買到 MCT 產品了。但看到團隊如何真正推動核心業務的發展,以及我們在核心監控業務中看到的情況,我們在創新通路合作夥伴方面取得的成就,以及我們在MCT類別中看到的情況,即使沒有——我們認為新的MCT產品是一個更好的產品。我們知道,市場佔有率的機會是真實存在的。

  • What we're validating in our Sleep pilots gives us confidence that sleep is going to be a nice contributor to us well out into the future. And so I am very excited by where the company can go and the position that we're in. But I think for the time being, let's get to the $1 billion in '27 and then we'll start to think about how we reset those expectations further out. On the profitability side, I'll let Dan speak to it, but he's done a terrific job driving the team and just identifying where those levers are at in our company. I think we've got great confidence on how we drive into the 15%, and then we know we can go beyond that, but I'll let him speak a little bit more to that.

    我們在睡眠試點計畫中驗證的結果讓我們相信,睡眠在未來很長一段時間內都將對我們大有裨益。因此,我對公司的未來發展方向和我們所處的地位感到非常興奮。但我認為,就目前而言,我們先實現 2027 年 10 億美元的目標,然後再開始考慮如何調整更長遠的預期。在獲利能力方面,我會讓丹來談談,但他在領導團隊和確定公司獲利槓桿方面做得非常出色。我認為我們對如何進入前 15% 有很大的信心,而且我們知道我們還能超越這個目標,但我還是讓他再多談談這方面吧。

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Yeah. Thanks for the question, Nathan. So I'd say the formula for Q4 and 2026 are kind of consistent. Driving efficiencies within gross margin and G&A while reinvesting back in the business, both for commercial initiatives and as well as a number of the innovation efforts that we're focused on. So we always try to set up a balanced plan where we're driving efficiencies, really looking at gross margin. You heard my comments about gross margin stepping up incrementally in 2026.

    是的。謝謝你的提問,內森。所以我認為第四季和 2026 年的公式基本上一致。在提高毛利率和一般及行政費用效率的同時,將利潤再投資於業務,包括商業舉措以及我們正在重點關注的多項創新舉措。所以我們總是努力製定一個平衡的計劃,在提高效率的同時,真正關注毛利率。你們都聽到了我關於2026年毛利率逐步提高的說法。

  • And then within OpEx, certainly, continuing to drive leverage within that G&A line. And that's leveraging our global footprint, leveraging the global business service center that we have stood up now for the last few years. There's a number of G&A functions that are fixed and won't need to scale with volume. And then certainly, FDA remediation, as you noted, as that moderates overtime, that would be a nice source of leverage for us as well. And then we look at that and then decide what should be reinvested back into the business, both from a sales and marketing standpoint and an R&D standpoint. And look to have a balanced plan that is ultimately driving to deliver long-term value for shareholders.

    在營運支出方面,當然也要持續提高一般及行政費用方面的槓桿作用。這就是利用我們的全球佈局,利用我們過去幾年建立的全球業務服務中心。有一些管理費用是固定的,不需要隨著業務量的增加而增加。當然,正如您所指出的,FDA 的補救措施會隨著時間的推移而有所緩和,這對我們來說也是一個很好的籌碼來源。然後我們會分析這些數據,並決定應該從銷售和行銷的角度以及研發的角度將哪些資金重新投入到業務中。並力求制定一個平衡的計劃,最終為股東創造長期價值。

  • Nathan Treybeck - Equity Analyst

    Nathan Treybeck - Equity Analyst

  • If I can just follow up with one more. Just on chart-scrapping, I guess how do you expect a potential tailwind could unfold? Would it be a directive from regulators to do confirmatory diagnoses or would it be more self-driven by the providers? And then just beyond the potential near-term tailwind, are you hearing any concerns from your customers that have high Medicare Advantage population that continuing asymptomatic screening to be risky for them?

    如果可以的話,我再補充一個問題。僅從圖表分析來看,你認為潛在的順風會如何發展?監管機構會下令進行確診,還是醫療服務提供者會主動這樣做?此外,除了近期可能出現的利多因素之外,您是否聽到您的客戶(尤其是那些擁有大量 Medicare Advantage 人群的客戶)擔心繼續進行無症狀篩檢會給他們帶來風險?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • No. I would say, certainly not on the latter part of that question. As a matter of fact, in the discussions we're having with customers, and I sat with one just about two weeks ago, who's been a terrific partner of ours, they're expanding their program even further. Just they're starting to see real cost data accumulate now that their program has been in place for over a year that is demonstrating very clearly that they are able to reduce the cost of caring for these populations. So they'll end up, I believe, expanding that population, and that's going to be a nice opportunity for us, but I think it's indicative of even where the future of more of these partners end up heading. So I'm excited by where that goes.

    不。對於問題的後半部分,我的回答肯定是否定的。事實上,在我們與客戶的討論中(大約兩週前我與一位客戶進行了交流,他一直是我們非常棒的合作夥伴),他們正在進一步擴大他們的計劃。現在他們的計畫已經實施一年多了,他們開始看到真實的成本數據不斷積累,這些數據非常清楚地表明,他們能夠降低照顧這些人群的成本。所以我相信,他們最終會擴大這個群體,這對我們來說是一個很好的機會,但我認為這也預示著更多合作夥伴的未來發展方向。所以我很期待它的發展方向。

  • I think your specific question on chart-scraping, I expect this is going to be much more of a self-driven behavior and change and maybe approach of some of these folks from the past. I think that they want to have the confirmatory records in the patient records, having a zero report there that demonstrates very clearly where an arrhythmia is present or not is something that bolsters their own documentation and from the discussions we've had, I I expect this will be a tailwind for us. But again, our approach has always been around these sort of things, let them play out. As they do play out as we learn more, then we can speak more about them and even roll them into forward-looking expectations when the time is right. But I think the majority of this from what I can tell and what I expect is probably more of a self-driven change in behavior as well as anticipated.

    我認為你提出的關於圖表抓取的具體問題,我預計這將更多地是一種自我驅動的行為和改變,也可能是過去一些人的方法。我認為他們希望在病患記錄中保留確認記錄,一份零報告可以非常清楚地表明是否存在心律不整,這可以加強他們自己的文件記錄。根據我們進行的討論,我預計這將對我們有利。但是,我們對待這類事情的態度一直都是順其自然。隨著我們對它們的了解越來越多,當它們逐漸顯現時,我們可以更多地談論它們,甚至在時機成熟時將它們納入對未來的預期中。但我認為,就我所見所聞以及我的預期而言,這其中大部分可能更多的是一種自我驅動的行為改變,也是人們所預料到的。

  • Operator

    Operator

  • David Rescott, Baird.

    David Rescott,貝爾德。

  • David Rescott - Senior Research Analyst

    David Rescott - Senior Research Analyst

  • Great. Congrats on all the progress in '25. Dan, you mentioned that pricing was favorable in 2025. I think you pointed to improvements in the estimated collections of reserves were a factor there. So wondering if you could maybe just unpack exactly what's going on in that front? And when you think about 2026, I think you called out pricing as being relatively flat this year. I believe there is an uplift broadly in the reimburse rate from Medicare this year in '26. So can you help us understand maybe why pricing should be flat this year relative to the Medicare uplift and then relative to some of the pricing comments you made for 2025?

    偉大的。恭喜你們在2025年取得的所有進展。丹,你提到2025年的價格會很優惠。我認為你指出的儲備金估算值的增加是其中一個因素。所以我想知道您能否具體解釋一下這方面的情況?展望 2026 年,我認為你曾指出今年的價格將相對穩定。我認為今年(2026年)聯邦醫療保險的報銷率總體上有所提高。那麼,您能否幫助我們理解,為什麼今年的價格相對於醫療保險的上漲以及您之前對 2025 年價格的一些評論而言應該保持不變?

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Yeah. Thanks, Dave. Happy to take those questions, and maybe start -- we did start out 2025 with guidance, expecting price to be down low single digits for the year. Ultimately, the year did come in call it, up low single digits. So we weren't able to over-deliver on the price expectations and guidance that we gave for 2025.

    是的。謝謝你,戴夫。樂意回答這些問題,也許可以開始——我們在 2025 年初發布了業績指引,預計當年價格將下降個位數百分比。最終,這一年還是以個位數成長告終。因此,我們未能實現我們先前對 2025 年給出的價格預期和指導。

  • A few things behind that, certainly, product mix was a portion of that. But as noted in that Q4 price benefit, we book a net revenue amount that is an estimate of what we expect to ultimately collect and that's gross revenue less contractual allowance. As we go through the collection cycle, we're comparing actual collections versus what was estimated and we true up our estimate kind of as appropriate. And -- that's what we saw in the fourth quarter. Our collections were running ahead of our estimates.

    這背後有很多因素,當然,產品組合是其中一部分。但正如第四季度價格收益中所指出的,我們確認的淨收入金額是對我們預計最終收取的金額的估計,即總收入減去合約津貼。在收款週期中,我們會將實際收款與預估收款進行比較,並視情況修正預估收款。而——這就是我們在第四節比賽中看到的情況。我們的收款進度超出了預期。

  • And so we had a true-up of, call it, low single-digit millions in the quarter. It is onetime in the quarter, but I would say the performance of our market access teams, our payer contracting, our revenue cycle operations, that performance certainly should sustain and give us a really solid foundation as we think about price in '26 and beyond.

    因此,本季我們進行了一次調整,調整金額約為數百萬美元。雖然這只是季度內的一次事件,但我認為,我們市場准入團隊、支付方合約、收入周期營運方面的表現,肯定能夠持續下去,並為我們思考 2026 年及以後的價格問題奠定一個非常堅實的基礎。

  • We're not going to factor that into guidance just yet, but certainly a good tailwind for us. You did comment on the Medicare rates being up in 2026. That is specific to Zio Monitor to long-term continuous monitoring. Medicare overall is 25% of our business, as you know. In the MCT category or AT Medicare rates are slightly down year over year in 2026.

    我們目前還不會將此因素納入指導方針,但這無疑是一個利好因素。您確實提到 2026 年醫療保險費率將會上漲。這是 Zio Monitor 特有的長期連續監測功能。如您所知,醫療保險業務占我們總業務的 25%。2026 年,MCT 類別或 AT Medicare 費率較去年同期略有下降。

  • But as you put it all together, mix, channel mix, product mix, the right way to set up the year for 2026 is ultimately price being flat relative to 2025. If we can over-deliver on that, great, like we did in 2025, but we want to set up the year kind of in an appropriate way.

    但綜合考慮所有因素,包括組合、通路組合、產品組合,2026 年的正確策略最終是價格與 2025 年持平。如果我們能超額完成目標,那就太好了,就像我們在 2025 年所做的那樣,但我們希望以合適的方式為這一年做好準備。

  • Operator

    Operator

  • Michael Polark, Wolfe Research.

    邁克爾·波拉克,沃爾夫研究中心。

  • Mike Polark - Equity Analyst

    Mike Polark - Equity Analyst

  • I want to better understand the mobile gateway comment for next gen MCT. How is this different than the existing gateway? Is this -- is this an app on a patient's own smartphone? Is that the illusion or does mobile gateway mean something different? Any color would be welcome.

    我想更能理解下一代MCT的行動網關評論。這與現有的網關有何不同?這是——這是患者自己的智慧型手機上的應用程式嗎?那隻是錯覺嗎?還是行動網關另有意義?任何顏色都可以。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah. Mike, thanks for that question. I'm glad you asked it so that we can clarify. The initial version of the mobile gateway will essentially be a smart device, but able to be locked in to where it only communicates directly with our Zio AT product. So we will provide that each and every time that the Zio new Zio MCT product is shifted and delivered to a patient, and they'll use that as a way for the Zio MCT product to communicate through that gateway. But it will be locked with the potential to have a Zio App included on it. But it will not be on their own smart device.

    是的。麥克,謝謝你的提問。很高興你問了這個問題,這樣我們才能澄清。行動網關的初始版本本質上是一個智慧型設備,但可以鎖定,使其只能與我們的 Zio AT 產品直接通訊。因此,每次 Zio 新的 Zio MCT 產品被轉移並交付給患者時,我們都會提供該服務,他們將使用該服務作為 Zio MCT 產品透過該網關進行通訊的方式。但它將被鎖定,並且有可能預先安裝 Zio 應用。但不會顯示在他們自己的智慧型裝置上。

  • I think that a future iteration of the product, you certainly can see us moving to a patient's own smartphone that has some other complications with it that need to be worked through. But certainly, you see that in other marketplaces, I think back to the days of CGM and DexCom certainly, we ended up going down that pathway. But that will not be the first that we had down here with Zio MCT. It will be a locked smartphone capability only to be utilized with the Zio MCT product.

    我認為,在產品的未來迭代中,我們肯定會看到我們轉向使用患者自己的智慧型手機,但這其中也存在一些需要解決的其他複雜問題。但當然,在其他市場,你也能看到這種情況。回想起 CGM 和 DexCom 的時代,我們最終也走上了這條路。但這並不是我們第一次在這裡與 Zio MCT 發生衝突。這將是一項僅限與 Zio MCT 產品一起使用的智慧型手機專屬功能。

  • Operator

    Operator

  • David Saxon, Needham.

    大衛‧薩克森,尼德姆。

  • David Saxon - Equity Analyst

    David Saxon - Equity Analyst

  • I had a follow-up on the innovative channel just around when the right time is to start engaging those partners around repeat monitoring. Is that something you can standardize either across the channel or partner by partner? And I mean you guys are good at generating data. So like is there any data you have internally that shows there is some value to monitoring after a certain period of time?

    我跟進創新管道,恰好是在開始與合作夥伴就重複監測進行溝通的最佳時機。這是可以在整個管道內還是逐一合作夥伴地進行標準化的嗎?我的意思是,你們很擅長收集數據。那麼,你們內部是否有任何數據表明,在一段時間後進行監控是有價值的?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah, I think it's a great question. And to be honest with you, I think with every one of these channel partners, the discussion is a little bit unique and different to their own practices. Some will talk about repeat testing every every 12 months, others will talk about it every three years. I do think, for the most part, everybody is talking about some sort of repeat testing, but what the frequency looks like is just too early to identify just yet. I think that importantly, once you get to a confirmatory diagnosis and you start to treat that patient, you're going to want to make sure that, that arrhythmia is either being addressed or if it's reappeared, you're going to want to know that, which naturally leads into why there would be repeat testing here.

    是的,我覺得這是一個很好的問題。坦白說,我認為與每個通路合作夥伴的討論都略有不同,與他們各自的實踐有所不同。有些人會說每 12 個月重複測試一次,有些人會說每三年重複測試一次。我認為,目前大多數人都在談論某種形式的重複檢測,但檢測頻率如何還為時過早,無法確定。我認為重要的是,一旦確診並開始治療患者,你就需要確保心律不整得到控制,或者如果復發,你需要知道這一點,這自然就引出了為什麼這裡需要重複測試。

  • At the same time, I think that the further we go into this, payers are understanding sort of the cost benefit associated with these monitoring programs. And I think that annual monitoring, annual patching is something that you could see start to be used from a risk perspective to identify how they even think about pricing their programs with their patient population. So there's a lot of reasons to see this move towards more of an annual sort of monitoring program, but it's still too early to speak to exactly how that's going to play out. But those are discussions that are being had, and I think there will be some aspect to annual monitoring in these partner programs.

    同時,我認為隨著我們對此的深入研究,支付方也逐漸了解這些監測計畫所帶來的成本效益。我認為,從風險角度來看,年度監測、年度修補可能會開始被採用,以確定他們如何考慮針對其患者群體制定專案定價。因此,有許多理由認為這種趨勢會朝著年度監測計畫的方向發展,但現在談論它將如何具體實施還為時過早。但這些都是正在進行的討論,我認為這些合作夥伴計畫中將會包含一些年度監測的環節。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • Suraj Kalia, Oppenheimer.

    Suraj Kalia,奧本海默。

  • Suraj Kalia - Analyst

    Suraj Kalia - Analyst

  • Congrats on a great quarter. Can you hear me all right?

    恭喜你本季表現出色。你聽得清楚我說話嗎?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah, we got you.

    是的,我們罩著你。

  • Suraj Kalia - Analyst

    Suraj Kalia - Analyst

  • Perfect. So Quentin, many calls going on. Forgive me if you've already talked about this. Our math suggests you guys grew Zio AT, roughly around 30% or higher click. When you look at the bridge device, so the gateway device for Zio AT, I understand in past conversations there have been comments about like there were some concerns about -- patient concerns about the bridge device, hence this shift to cellular for the Zio MCT product, hence this delay, right?

    完美的。所以昆汀,你現在有很多電話在打。如果您之前已經談過這個主題,請原諒我。我們的計算表明,你們的 Zio AT 成長了大約 30% 或更高。當你查看橋接設備,也就是 Zio AT 的網關設備時,我了解到在過去的對話中,有人提到過一些關於橋接設備的擔憂——患者對橋接設備的擔憂,因此 Zio MCT 產品轉向了蜂窩網絡,因此出現了延遲,對嗎?

  • More specifically, Quentin, can you tell us what was the challenge with the bridge device because so far, unless my math is wrong, you guys have still navigated very effectively growing at 30% clip 15% or close thereof MCT shared. Hopefully, you got my question, Quentin.

    更具體地說,昆汀,你能告訴我們橋接設備面臨的挑戰是什麼嗎?因為到目前為止,除非我的計算有誤,否則你們仍然非常有效地實現了 30% 的成長,MCT 股份佔比接近 15%。昆汀,希望你明白我的問題。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah. I got it, Suraj. And thank you for the question. Just to clarify on AT and just to speak to the strength of that product, and I put this in our prepared remarks as well. It's growing at more than twice the rate of the overall company average. So for the year, our Zio AT product actually grew north of 50%. I think that's important to note just considering the success in that MCT category that we're having with a product that we know will be enhanced with the new Zio MCT offering. So our momentum there is incredibly strong.

    是的。我明白了,蘇拉傑。謝謝你的提問。關於 AT,我想澄清一下,也想談談該產品的優勢,這點我也寫進了我們準備好的演講稿裡。它的成長速度是公司整體平均速度的兩倍以上。因此,今年我們的 Zio AT 產品銷售量實際成長超過 50%。我認為這一點很重要,因為我們目前在MCT類別中取得了成功,而且我們知道,隨著新的Zio MCT產品的推出,該產品將會得到進一步的提升。因此,我們在該領域的勢頭非常強勁。

  • To Dan's point earlier, we did not set up our guidance that way for 2026. But if you look at the last 5 quarters, we've demonstrated the ability to grow that at nearly twice the overall rate of our company. So we're bullish on the category for sure, and we're excited by it.

    正如丹之前提到的,我們並沒有那樣制定 2026 年的指導方針。但如果你看看過去 5 個季度,你會發現我們已經證明,我們有能力以幾乎是公司整體成長兩倍的速度實現這一目標。所以我們非常看好這個品類,也對它感到興奮。

  • When you think about the mobile gateway, as we were working through this with the FDA, there were some questions around cybersecurity that -- we're certainly going to require us to design some incremental capabilities into our old gateway if we were going to address those questions. And the challenge of that was that, we knew we were going to have to move to a new gateway at some point in the future. And rather than take the time today to design those incremental cybersecurity features and capability into the old gateway only to obsolete it in the next round of future innovation that we would introduce after this MCT product, we made the decision to go ahead and just bring it right into a new mobile gateway that addresses the cybersecurity concerns.

    當你考慮到行動網關時,正如我們與 FDA 一起研究的那樣,存在一些關於網路安全的問題——如果我們要解決這些問題,我們肯定需要在舊網關中設計一些增量功能。而當時的挑戰在於,我們知道將來某個時候我們必須遷移到一個新的網關。與其今天花時間在舊網關中設計這些漸進式的網路安全特性和功能,卻在下一輪未來創新中將其淘汰(而下一輪創新將在 MCT 產品之後推出),我們決定直接將其整合到一個新的行動網關中,以解決網路安全問題。

  • So this is all around making the right decisions for the long-term health of the business. We know that we can address these. We see a clear path to getting a product approval, but it does take us to a mobile gateway sooner than what we had expected, and that requires a bit of time there. So that's contemplated in all of the the timelines that we've put out there, but getting to the new mobile gateway is going to address those concerns around the cybersecurity aspect that we would have had to have done in the old gateway just doesn't make sense to really spend the time, effort, resources, putting it into something that we knew was going to be obsoleted.

    所以這一切都是為了企業的長遠健康發展而做出正確的決策。我們知道我們可以解決這些問題。我們看到了獲得產品批准的明確途徑,但這確實比我們預期的要早地讓我們進入行動網關階段,而這需要一些時間。所以,在我們公佈的所有時間表中都考慮到了這一點,但啟用新的行動網關將解決網路安全方面的擔憂,而我們在舊網關上所做的這些擔憂是沒有意義的,因為把時間、精力、資源投入到我們明知會過時的東西上是沒有意義的。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    大衛羅曼,高盛集團。

  • David Roman - Analyst

    David Roman - Analyst

  • Maybe you could talk a little bit more about the referral channel within the innovative partners and the extent to which you're seeing consumer-based devices drive patients into that channel, maybe the degree to which some of the false positives that come off of those devices are actually increasing testing volume? And then maybe if you can tie that back to some of the AI questions you got earlier, maybe would help just complete the picture a little bit of how to think about the implications.

    或許您可以再多談談創新夥伴內部的轉診管道,以及您認為消費者設備在多大程度上將患者引入該管道,或許還可以談談這些設備產生的一些假陽性結果在多大程度上實際上增加了檢測量?如果你能把這些與你之前提出的一些人工智慧問題連結起來,或許就能幫助你更全面地了解這些影響。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah. Look, it's an interesting question because I think if you look across our business, there's no question that wearable devices -- forget just the innovative channel partners. Just in general, wearable devices have tended to be a pretty good regenerator for our company, meaning that folks or patients show up in their clinicians' office with a wearable device indicating maybe there's an arrhythmia or something there that needs to be monitored. And ultimately, a Zio gets prescribed for that patient and they get to the fact that they can get a real confirmed diagnosis. And so wearables have been a terrific lead generator for us.

    是的。你看,這是一個有趣的問題,因為我認為,如果你縱觀我們的業務,毫無疑問,可穿戴設備——更不用說那些創新的通路合作夥伴了。總的來說,穿戴式裝置對我們公司來說一直是一個很好的復甦器,這意味著人們或病人會帶著穿戴裝置來到臨床醫生的辦公室,表明他們可能有心律不整或其他需要監測的問題。最終,醫生給這位病人開了 Zio 處方,病人也終於得到了確診。因此,穿戴式裝置一直是我們非常棒的潛在客戶開發工具。

  • But you look at these innovative channel partners, whether it's a wearable or not. And quite honestly, I don't see the wearables sort of leading patients into these programs. These are programs with our innovative channel partners that they're very particular around who they're going to monitor. You think about our Lucem AI capabilities where we're identifying patient populations proactively by looking through medical records where we can say, look, we have a pretty good idea and belief that, that patient likely has an arrhythmia and then you get a patch on that patient. And those accuracy rates have been as high as 90% in these early trials.

    但看看這些創新通路合作夥伴,無論他們銷售的是穿戴式裝置還是其他產品。坦白說,我不認為穿戴式裝置會引導患者參與這些計畫。這些計畫是與我們創新通路合作夥伴共同進行的,他們對要監測的對象非常挑剔。想想我們 Lucem 的人工智慧功能,我們透過查看醫療記錄主動識別患者群體,然後我們可以說,你看,我們有相當好的想法和信心,該患者可能患有心律失常,然後給該患者貼上貼片。在這些早期試驗中,準確率高達 90%。

  • But every one of these partners are typically profiling a population within their coverage universe, whether it's a comorbid disease, state of diabetes, COPD, CKD, sleep, you can go down the list, they're putting a patch on those patients to get to a confirmed diagnosis. That is what they're looking for.

    但這些合作夥伴通常都會對其覆蓋範圍內的特定人群進行分析,無論是合併症、糖尿病、慢性阻塞性肺病、慢性腎病、睡眠問題等等,不勝枚舉,他們都會給這些患者貼上標籤,以確診病情。這就是他們想要的。

  • And in the case, if (inaudible) is something that is part of their model, they want that confirmed diagnosis, documented diagnosis in their records as further support. And so I don't see the wearables as being something that's really driving the innovative channel partners at this point in time. I do think it's been a nice lead generator for us in the past, but these innovative channel partners are pretty particular around the populations that they're targeting and going after. And then what I'm encouraged by, and I think you'll see this data later this year, you're going to see some really compelling cost reduction capabilities coming out of these programs that, frankly, is allowing us to expand the programs within these channel partners. So excited about what we're seeing.

    如果(聽不清楚)是他們模型的一部分,他們希望在他們的記錄中得到確認的診斷和記錄作為進一步的支持。因此,我認為在現階段,穿戴式裝置並不是真正推動創新通路夥伴發展的因素。我確實認為它過去一直是我們不錯的潛在客戶開發管道,但這些創新通路合作夥伴對他們的目標人群和目標客戶群都非常挑剔。令我感到鼓舞的是,我認為你們會在今年稍後看到這些數據,你們將會看到這些項目帶來一些非常有說服力的成本降低能力,坦白說,這使我們能夠擴大這些通路合作夥伴的項目規模。看到眼前的一切,我感到無比興奮。

  • But I don't think wearables are necessarily driving innovative channel partners. I don't think wearables address what the channel partners are after. Frankly, they want an accurate confirmed diagnosis, and that's something that Zio provides, and they're leaning-in to us for that.

    但我認為穿戴式裝置未必會推動通路夥伴進行創新。我不認為穿戴式裝置能夠滿足通路合作夥伴的需求。坦白說,他們想要的是準確的確診,而這正是 Zio 所能提供的,他們也正因此而向我們尋求幫助。

  • Operator

    Operator

  • Stephanie Piazzola, Bank of America.

    史蒂芬妮·皮亞佐拉,美國銀行。

  • Stephanie Piazzola - Analyst

    Stephanie Piazzola - Analyst

  • I wanted to follow up on the innovative channel partnerships and how the 2026 guide includes a step-up in the '25 exit rate and just any help on how to think about what that exit rate was I think, volume from innovative partners have been low single digits, but stepping up each quarter. So did that trend continue in Q4? And is it still around low single digits or more mid-single-digit range? And any other help on how to think about the step-up factored into 2026.

    我想跟進創新通路合作夥伴關係,以及 2026 年指南中提到的 2025 年退出率的提升,以及任何關於如何理解該退出率的幫助。我認為,來自創新合作夥伴的數量一直只有個位數,但每季都在增加。那麼,這趨勢在第四季是否延續了?現在還是在個位數低點還是個位數中位數?以及任何其他有助於考慮 2026 年成長因素的幫助。

  • Daniel Wilson - Chief Financial Officer

    Daniel Wilson - Chief Financial Officer

  • Yeah, Stephanie. Good question there. So innovative channel partner, I would continue to point to low single digits as a percentage of overall business. We did see that trend positively upward as we were going through 2025. My comments on exit rate, if you took revenue from innovative channel in Q4 and annualize that, that's essentially or gets you a good amount of what we have contemplated in guidance.

    是的,史蒂芬妮。問得好。因此,對於創新通路合作夥伴,我將繼續指出,其業務佔比將保持在個位數以下。我們確實看到,在展望 2025 年的過程中,這一趨勢呈現正上升態勢。關於退出率,我的評論是,如果你把第四季度創新管道的收入乘以年化,這基本上就等於或至少能讓你得到我們在業績指引中所設想的大部分內容。

  • And then also mentioned, we have had new partners come on board in both Q4 and Q1. So feel good about that base of business continuing to grow. I'll reiterate though, that is an emerging part of our business. The visibility there isn't as great as it is in our core business. Each of our partners are unique in terms of how quickly they ramp their business, the patients that they're proactively monitoring.

    此外,他們也提到,我們在第四季和第一季都有新的合作夥伴加入。所以,可以欣慰的是,這部分業務基礎仍在持續成長。不過我還是要重申,這是我們業務中一個新興的部分。那裡的可見度不如我們核心業務那麼高。我們的每個合作夥伴在業務拓展速度和主動監測的患者方面都各有不同。

  • And so for all those reasons, we're going to be thoughtful. We want to make sure we don't get ahead of ourselves. But really excited about what that business can contribute in 2026, both from a guidance standpoint as well as potentially upside.

    因此,出於以上種種原因,我們會深思熟慮。我們想確保自己不會操之過急。但對於該業務在 2026 年能夠做出的貢獻,無論是從業績指引還是潛在的成長空間來看,我都感到非常興奮。

  • Operator

    Operator

  • John Young, Canaccord Genuity.

    John Young,Canaccord Genuity。

  • John Young - Equity Analyst

    John Young - Equity Analyst

  • I wanted to ask on Epic Aura accounts. I don't think it was discussed. Was that the 75 number that you provided in the prepared remarks. And any commentary on volume improvements that you're seeing from Aura. And is that embedded in the core company guidance expectations for 2026? Or is that another source of potential upside?

    我想問一下關於Epic Aura帳號的問題。我認為這個問題沒有被討論過。那是你在準備好的演講稿中提到的75這個數字嗎?還有,關於Aura在音量方面的改進,您有什麼看法?這是否已納入公司 2026 年的核心業績預期?或者說,這是另一個潛在的上漲空間?

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Yeah. Good question. Epic continues to be a terrific partner for us and one that we continue to be excited about. Just to be clear, I mentioned top 75 of 100, that's all integrated systems, not just Epic system. So just to be clear, it's across all EHR platforms, but Epic is a big part of that.

    是的。問得好。Epic一直是我們非常棒的合作夥伴,我們對與他們合作感到非常興奮。需要說明的是,我提到的是前 75 名(共 100 名),這指的是所有整合系統,而不僅僅是 Epic 系統。所以說清楚點,它適用於所有電子病歷平台,但 Epic 是其中很重要的一部分。

  • Epic itself continues to perform incredibly well. I would tell you, we had a record number of Epic integrations performed in the fourth quarter. We're on pace to set another record in the first quarter of this year. So it's growing quite nicely, and the pipeline is incredibly strong, and that's going to continue to play out over the course of the year.

    Epic Games 本身的表現仍然非常出色。我可以告訴你,我們在第四季度完成了創紀錄數量的 Epic 系統整合。我們預計今年第一季再創佳績。所以它的發展勢頭相當不錯,項目儲備非常充足,這種情況將在今年繼續保持下去。

  • We know that when we get integrated with these folks, our data would tell us 6 months post integration, we see roughly a 25% increase in overall prescribing volume. We're not setting up our guidance that way. Again, I think we'd like to be thoughtful on those things and let some of those play through before we would factor all that into guidance. But the Epic partnership and the integrations associated with it have been going very, very well and I would say, ahead of plan. And we're bullish on what Q1 and the rest of this year is going to look like.

    我們知道,當我們與這些人整合後,我們的數據顯示,整合後 6 個月,處方總量大約會增加 25%。我們的指導方針並非如此制定。再次強調,我認為我們應該認真考慮這些因素,讓其中一些因素發揮作用,然後再將所有這些因素納入指導方針中。但與 Epic 的合作以及相關的整合工作進展得非常順利,可以說,比計畫還要順利。我們對第一季以及今年剩餘時間的前景都非常樂觀。

  • Operator

    Operator

  • Thank you. At this time, I would now like to pass the call back over to the management team for any closing remarks.

    謝謝。現在,我想把電話轉回管理團隊,請他們作總結發言。

  • Quentin Blackford - President, Chief Executive Officer, Director

    Quentin Blackford - President, Chief Executive Officer, Director

  • Well, thank you. As we close, I just want to take a moment to thank the iRhythm employees around the globe. The progress that we shared today, the strong growth, expanding profitability, the increasing impact that we're making on patients, it's only made possible by their dedication, the expertise and the relentless focus that they demonstrate each and every day on doing the right thing for our patients and our customers. It's their work ethic, it's their commitment that continues to set us apart, especially as we operate in an increasingly complex environment.

    謝謝。最後,我想藉此機會感謝全球各地的 iRhythm 員工。我們今天分享的進展、強勁的成長、不斷擴大的獲利能力、以及我們對患者日益增長的影響,都離不開他們的奉獻精神、專業知識以及他們每天堅持不懈地為我們的患者和客戶做正確的事情。正是他們的職業道德和敬業精神,使我們始終脫穎而出,尤其是在我們營運環境日益複雜的今天。

  • And as I think ahead of entering into our 20th year, I couldn't be more proud of the team and more confident in what we're going to accomplish together. And I just want to put a big shout out to the team. Congratulations on all you've done and look forward to the future.

    展望公司成立20週年,我為團隊感到無比自豪,也對我們共同的成就充滿信心。我還要特別感謝一下團隊。恭喜你所取得的一切成就,並期待你未來能有更大的成就。

  • Thank you to the folks that are on the call today. I look forward to seeing all of you guys in the near future and look forward to a great 2026. Thank you.

    感謝今天參加電話會議的各位。我期待在不久的將來見到大家,並期待美好的2026年。謝謝。

  • Operator

    Operator

  • Thank you. That will conclude today's call. Thank you for your participation. You may now disconnect your lines.

    謝謝。今天的電話會議到此結束。感謝您的參與。現在您可以斷開線路了。